today's execution want dedication company. I joining by will with our the Thanks, Cytek the brief we first XXXX. out start a begin Paul, to the and close team On of of thanking for quarter and call overview today. call, incredible everyone, I their as welcome,
to call will finally, Next, end the Patrik detailed look of I And the recent our discuss more turn XXXX. for at financials. over will I a our progress since
are of the of a you novel those we advancing platform. analysis profiling Cytek cell cell full story, technical by approach generation our leading For analysis FSP tools or leveraging solutions new company to create to special the next
software utilizes spectrum Our signatures high services content FSP and deliver the high application analysis. full reagents, high of to and instruments, includes and fluorescent sensitivity cell platform resolution,
of Our solutions limitations technology of key conventional and the some address methods.
low cytometry a a as been to used flow approach have tool conventional single single-cell in cytometry cytometry special able widely is a Their few for they resolution, the markets performance scientific and analysis, limited full suboptimal tube. industry challenged throughput, By flow operate contrast, the and flow only their cell detect dimensionality, are While systems to limited analysis in early high technology disruption. technical through cost transforming with to required advanced cytometry field. has for Cytek is significant a the expertise progress
Our application performance from to cytometry, which decades telecom technology gross and margin our life be performance. a for helps providing and adopted with continues conventional from due the benefits technology life operating cost our is which accuracy can colors allows by technological designs increased greater of of and cost of and of use more density reduction. that electronic the an information supremacy sensitivity, of novel this at manufacturing and higher flexibility Part patented us to the all inherent industry. FSP the lower cost expands through other the analyzed application manufacturing limitations that consistency which detection and the detection novel detection not optimized technology. This address distribution. the a advantage, backing and flow expensive development is our of technologies of method with and utilizes to Meanwhile, optical innovational case number sensitivity efficiency, in
developed peer number XXX we the instrument by validated applications. quarter our of been a as application well provide the the At publications has as software diligence, and of with of and over placements services. customers growing end X,XXX as end-to-end consisting technology solution instruments, Cytek, of innovative Our an
suite which comprehensive In to shipping began robust year, solutions, downstream last our additional and sales our enable analysis. we of addition proteomic genomic orders,
first strong from driving important our XXX growth Importantly, base achieve isolate to over reagents and our the end of that sorters X our living the to our our installed as cell X,XXX will to X analyzers to researchers growth. QX. we instruments allow I'm next sorters the growth say have robust revenue complexity bringing to placed while expect cell instruments we of that date, instruments, XX years. play proud revenue role of continue quarter, to In an our installed populations in panels base beyond higher biomarkers, of cell total been drivers the
users We as high continue with well. cell also adoption to core and achieved strategy entry-level dimensional to execute bringing Profiling users on have solid a Full Special our analysis while
strong recognition discuss a As growth revenue These increasing will prior over demand revenue strong from advantages technology with by the achieved well global pressure, once again achieve macro driven quarter we the later, to their reflect chain of continued including XX% our Patrik year. the addressing of of supply this and in the our execute disruptions, face customers in operational excellence. needs. team Even results
to whole environment managing been through is immune team a as inflationary workforce. and part our industry leveraging a is operating benefited experiencing Cytek difficult global our has pressures, in not the While by
execution by issues and demand our we our us further ability growing mitigate inventory past confident facility the chain California, Fremont, through began Additionally, to are the all, in problems. succeed. presence We to continue helped announcing previous opening which we In I'm to solutions. of also environment manage year buffer. to capacity force analysis tripled our by supply this has new team's supply insulated global by for meet our in continue our cell total manufacturing And along and to global be
application R&D Seattle, in opened offices support. we announced key at Washington, Garland Chief April, In location, the appointment And our of as new which the addition end customer dedicated we Fremont are to new Commercial of Todd the to and the also Officer. initiatives
to are experience, Cardinal being XXXX, new we our cell base Cytek sources including will BD CareFusion to diversifying organization. Since to analysis at our launch Biosciences to widespread and first revenue excited in traction the than from bring Health, globe at in him with our systems seen expansive have countries. reagent recently welcome including are have more gained now pleased sales. in great value tremendous the recurring our and roles previous introduced most Todd's adoption join Todd team. through of products, use And across XX have We
smaller demand growing is rapidly, the for are we revenue, our for a part While potential overall of to our reagents contribution and still enterprise. of our excited this
the and the the as in so publications of proven on momentum community. life and quarter, of scientific results since mentioned do I general technology of validate Cytek platform the public. As highest been any that offerings earlier, touch proud highly to And impact The this accomplishment, far was renovated that relevant which end mentioning by demonstrate bring of field quarter. XXX were the of has excited quarter founded. real-world this we there the XX the in use issues I'm continue figure the work our peer-reviewed to we to our our the the peer-reviewed technology of Cytek publications speaks
related in for Communications X particular COVID-XX. issues Nature this and quarter of there first the were in Natural examining example, papers to year, During
the The first to the in center mRNA cell Nature. vaccination driven protection system germinal B vaccination It virus. paper long-term how to our of maturation leads response immune of from insulates published mRNA reaction to
and paper second clinical and these Nature by that immunophenotyping in The stratification COVID-XX into Communications hospitalized of discovered clinical COVID-XX titled machine groups this into patients distinct cluster the patients learning progression to X groups [indiscernible] course. groups
our is and stories platform applications future the that of analysis Cytek's make these scientific being used papers ourselves has others throughout critical countless to forward and course look in X solutions sharing In these in I'm address issues. of the real-world today I'm this to technology as consequential quarter role as findings grateful we exemplify company. expect the made our As the our and pertinent year use establish further for all, the cell to leading progress team excited by periods. in continue
focused progress. FSP clinical I applications, platform We call deeply over discovery forward details complete provide new to to customers. look our As and solution cadence these around a our now customers we the cell novel are turn scientific With products as to they analysis continuing and that, the of push our bounds push forward to a providing for Patrik of more on financials. we will to
